Overview

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether melatonin prolonged-release (PR) and clonazepam are effective and safe in the treatment of rapid eye movement behavior disorder (RBD) of patients with Parkinson's disease (PD).

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Collaborator:

Kuhnil Pharmaceutical Co., Ltd.

Treatments:

Clonazepam
Melatonin